Review



s100a2 single cpg pyrosequencing data  (Pyrosequencing Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Pyrosequencing Inc s100a2 single cpg pyrosequencing data
    DNA methylation and gene expression of <t>S100A2;</t> the single CpG methylation levels of <t>S100A2</t> among (a) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (b) gliomas of grade II to IV and NTBs; (c) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); Gene expression patterns of S100A2 among (d) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (e) gliomas of grade II to IV and NTBs; and (f) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); (g) Representative S100A2 immunofluorescence staining (left) and the immunoreactivity scores (right) for FFPE samples of gliomas from grade II to IV; (h) Correlation of the single CpG methylation and gene expression of S100A2 in each database; (i) S100A2 single CpG pyrosequencing data in each GBM cell line; (j, k) Real-time PCR and western blots of S100A2 in each GBM cell line; * indicates both the comparison of tumors from TCGA vs. NTB from TCGA and GSE63347 respectively; # indicates each comparison of U251 vs. U373 (or U87 or T98G); NTBs = non-tumor brains; G-CIMP = glioma-CpG island methylator phenotype; IDH mut = IDH mutation; IDH wt = IDH wild type; GBM = glioblastoma; LGG = lower-grade glioma; FFPE = formalin-fixed paraffin-embedded
    S100a2 Single Cpg Pyrosequencing Data, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/s100a2 single cpg pyrosequencing data/product/Pyrosequencing Inc
    Average 90 stars, based on 1 article reviews
    s100a2 single cpg pyrosequencing data - by Bioz Stars, 2026-04
    90/100 stars

    Images

    1) Product Images from "Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas"

    Article Title: Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas

    Journal: Oncoimmunology

    doi: 10.1080/2162402X.2021.1902071

    DNA methylation and gene expression of S100A2; the single CpG methylation levels of S100A2 among (a) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (b) gliomas of grade II to IV and NTBs; (c) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); Gene expression patterns of S100A2 among (d) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (e) gliomas of grade II to IV and NTBs; and (f) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); (g) Representative S100A2 immunofluorescence staining (left) and the immunoreactivity scores (right) for FFPE samples of gliomas from grade II to IV; (h) Correlation of the single CpG methylation and gene expression of S100A2 in each database; (i) S100A2 single CpG pyrosequencing data in each GBM cell line; (j, k) Real-time PCR and western blots of S100A2 in each GBM cell line; * indicates both the comparison of tumors from TCGA vs. NTB from TCGA and GSE63347 respectively; # indicates each comparison of U251 vs. U373 (or U87 or T98G); NTBs = non-tumor brains; G-CIMP = glioma-CpG island methylator phenotype; IDH mut = IDH mutation; IDH wt = IDH wild type; GBM = glioblastoma; LGG = lower-grade glioma; FFPE = formalin-fixed paraffin-embedded
    Figure Legend Snippet: DNA methylation and gene expression of S100A2; the single CpG methylation levels of S100A2 among (a) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (b) gliomas of grade II to IV and NTBs; (c) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); Gene expression patterns of S100A2 among (d) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (e) gliomas of grade II to IV and NTBs; and (f) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); (g) Representative S100A2 immunofluorescence staining (left) and the immunoreactivity scores (right) for FFPE samples of gliomas from grade II to IV; (h) Correlation of the single CpG methylation and gene expression of S100A2 in each database; (i) S100A2 single CpG pyrosequencing data in each GBM cell line; (j, k) Real-time PCR and western blots of S100A2 in each GBM cell line; * indicates both the comparison of tumors from TCGA vs. NTB from TCGA and GSE63347 respectively; # indicates each comparison of U251 vs. U373 (or U87 or T98G); NTBs = non-tumor brains; G-CIMP = glioma-CpG island methylator phenotype; IDH mut = IDH mutation; IDH wt = IDH wild type; GBM = glioblastoma; LGG = lower-grade glioma; FFPE = formalin-fixed paraffin-embedded

    Techniques Used: DNA Methylation Assay, Gene Expression, CpG Methylation Assay, Immunofluorescence, Staining, Real-time Polymerase Chain Reaction, Western Blot, Comparison, Mutagenesis, Formalin-fixed Paraffin-Embedded

    The impacts of S100A2 expression on GBM cell lines, i.e., U251 (a–h) and U87 (i–p); Cell proliferation by CCK-8 assay in U251 (a) and U87 (i); Cell cycle alterations by PI-FACS analysis in U251 (b) and U87 (j); Cell apoptosis by Annexin V-FITC/PI double-staining method in U251 (c) and U87 (k); Cell migration by Transwell Chamber assay in U251 (d) and U87 (l); Cell invasion by Matrigel Chamber assay in U251 (e) and U87 (m); Western blots of the protein levels of S100A2, p -p65 and FGL2 in U251 (f) and U87 (n); Real-time PCR of S100A2 expression in U251 (g) and U87 (o); Protein levels of FGL2 in cell culture supernatants of U251 (h) and U87 (p) by ELISA assay; PI-FACS = propidium iodide-flow cytometric analysis; ELISA = enzyme-linked immunosorbent assay
    Figure Legend Snippet: The impacts of S100A2 expression on GBM cell lines, i.e., U251 (a–h) and U87 (i–p); Cell proliferation by CCK-8 assay in U251 (a) and U87 (i); Cell cycle alterations by PI-FACS analysis in U251 (b) and U87 (j); Cell apoptosis by Annexin V-FITC/PI double-staining method in U251 (c) and U87 (k); Cell migration by Transwell Chamber assay in U251 (d) and U87 (l); Cell invasion by Matrigel Chamber assay in U251 (e) and U87 (m); Western blots of the protein levels of S100A2, p -p65 and FGL2 in U251 (f) and U87 (n); Real-time PCR of S100A2 expression in U251 (g) and U87 (o); Protein levels of FGL2 in cell culture supernatants of U251 (h) and U87 (p) by ELISA assay; PI-FACS = propidium iodide-flow cytometric analysis; ELISA = enzyme-linked immunosorbent assay

    Techniques Used: Expressing, CCK-8 Assay, Double Staining, Migration, Transwell Chamber Assay, Boyden Chamber Assay, Western Blot, Real-time Polymerase Chain Reaction, Cell Culture, Enzyme-linked Immunosorbent Assay



    Similar Products

    s100a2 single cpg pyrosequencing data  (Pyrosequencing Inc)
    90
    Pyrosequencing Inc s100a2 single cpg pyrosequencing data
    DNA methylation and gene expression of <t>S100A2;</t> the single CpG methylation levels of <t>S100A2</t> among (a) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (b) gliomas of grade II to IV and NTBs; (c) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); Gene expression patterns of S100A2 among (d) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (e) gliomas of grade II to IV and NTBs; and (f) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); (g) Representative S100A2 immunofluorescence staining (left) and the immunoreactivity scores (right) for FFPE samples of gliomas from grade II to IV; (h) Correlation of the single CpG methylation and gene expression of S100A2 in each database; (i) S100A2 single CpG pyrosequencing data in each GBM cell line; (j, k) Real-time PCR and western blots of S100A2 in each GBM cell line; * indicates both the comparison of tumors from TCGA vs. NTB from TCGA and GSE63347 respectively; # indicates each comparison of U251 vs. U373 (or U87 or T98G); NTBs = non-tumor brains; G-CIMP = glioma-CpG island methylator phenotype; IDH mut = IDH mutation; IDH wt = IDH wild type; GBM = glioblastoma; LGG = lower-grade glioma; FFPE = formalin-fixed paraffin-embedded
    S100a2 Single Cpg Pyrosequencing Data, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/s100a2 single cpg pyrosequencing data/product/Pyrosequencing Inc
    Average 90 stars, based on 1 article reviews
    s100a2 single cpg pyrosequencing data - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    DNA methylation and gene expression of S100A2; the single CpG methylation levels of S100A2 among (a) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (b) gliomas of grade II to IV and NTBs; (c) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); Gene expression patterns of S100A2 among (d) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (e) gliomas of grade II to IV and NTBs; and (f) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); (g) Representative S100A2 immunofluorescence staining (left) and the immunoreactivity scores (right) for FFPE samples of gliomas from grade II to IV; (h) Correlation of the single CpG methylation and gene expression of S100A2 in each database; (i) S100A2 single CpG pyrosequencing data in each GBM cell line; (j, k) Real-time PCR and western blots of S100A2 in each GBM cell line; * indicates both the comparison of tumors from TCGA vs. NTB from TCGA and GSE63347 respectively; # indicates each comparison of U251 vs. U373 (or U87 or T98G); NTBs = non-tumor brains; G-CIMP = glioma-CpG island methylator phenotype; IDH mut = IDH mutation; IDH wt = IDH wild type; GBM = glioblastoma; LGG = lower-grade glioma; FFPE = formalin-fixed paraffin-embedded

    Journal: Oncoimmunology

    Article Title: Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas

    doi: 10.1080/2162402X.2021.1902071

    Figure Lengend Snippet: DNA methylation and gene expression of S100A2; the single CpG methylation levels of S100A2 among (a) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (b) gliomas of grade II to IV and NTBs; (c) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); Gene expression patterns of S100A2 among (d) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (e) gliomas of grade II to IV and NTBs; and (f) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); (g) Representative S100A2 immunofluorescence staining (left) and the immunoreactivity scores (right) for FFPE samples of gliomas from grade II to IV; (h) Correlation of the single CpG methylation and gene expression of S100A2 in each database; (i) S100A2 single CpG pyrosequencing data in each GBM cell line; (j, k) Real-time PCR and western blots of S100A2 in each GBM cell line; * indicates both the comparison of tumors from TCGA vs. NTB from TCGA and GSE63347 respectively; # indicates each comparison of U251 vs. U373 (or U87 or T98G); NTBs = non-tumor brains; G-CIMP = glioma-CpG island methylator phenotype; IDH mut = IDH mutation; IDH wt = IDH wild type; GBM = glioblastoma; LGG = lower-grade glioma; FFPE = formalin-fixed paraffin-embedded

    Article Snippet: DNA methylation and gene expression of S100A2; the single CpG methylation levels of S100A2 among (a) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (b) gliomas of grade II to IV and NTBs; (c) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); Gene expression patterns of S100A2 among (d) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (e) gliomas of grade II to IV and NTBs; and (f) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); (g) Representative S100A2 immunofluorescence staining (left) and the immunoreactivity scores (right) for FFPE samples of gliomas from grade II to IV; (h) Correlation of the single CpG methylation and gene expression of S100A2 in each database; (i) S100A2 single CpG pyrosequencing data in each GBM cell line; (j, k) Real-time PCR and western blots of S100A2 in each GBM cell line; * indicates both the comparison of tumors from TCGA vs. NTB from TCGA and GSE63347 respectively; # indicates each comparison of U251 vs. U373 (or U87 or T98G); NTBs = non-tumor brains; G-CIMP = glioma-CpG island methylator phenotype; IDH mut = IDH mutation; IDH wt = IDH wild type; GBM = glioblastoma; LGG = lower-grade glioma; FFPE = formalin-fixed paraffin-embedded Knockdown of S100A2 by two different shRNA sequences reduces the proliferation rates of U251 and U87 cells ( ).

    Techniques: DNA Methylation Assay, Gene Expression, CpG Methylation Assay, Immunofluorescence, Staining, Real-time Polymerase Chain Reaction, Western Blot, Comparison, Mutagenesis, Formalin-fixed Paraffin-Embedded

    The impacts of S100A2 expression on GBM cell lines, i.e., U251 (a–h) and U87 (i–p); Cell proliferation by CCK-8 assay in U251 (a) and U87 (i); Cell cycle alterations by PI-FACS analysis in U251 (b) and U87 (j); Cell apoptosis by Annexin V-FITC/PI double-staining method in U251 (c) and U87 (k); Cell migration by Transwell Chamber assay in U251 (d) and U87 (l); Cell invasion by Matrigel Chamber assay in U251 (e) and U87 (m); Western blots of the protein levels of S100A2, p -p65 and FGL2 in U251 (f) and U87 (n); Real-time PCR of S100A2 expression in U251 (g) and U87 (o); Protein levels of FGL2 in cell culture supernatants of U251 (h) and U87 (p) by ELISA assay; PI-FACS = propidium iodide-flow cytometric analysis; ELISA = enzyme-linked immunosorbent assay

    Journal: Oncoimmunology

    Article Title: Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas

    doi: 10.1080/2162402X.2021.1902071

    Figure Lengend Snippet: The impacts of S100A2 expression on GBM cell lines, i.e., U251 (a–h) and U87 (i–p); Cell proliferation by CCK-8 assay in U251 (a) and U87 (i); Cell cycle alterations by PI-FACS analysis in U251 (b) and U87 (j); Cell apoptosis by Annexin V-FITC/PI double-staining method in U251 (c) and U87 (k); Cell migration by Transwell Chamber assay in U251 (d) and U87 (l); Cell invasion by Matrigel Chamber assay in U251 (e) and U87 (m); Western blots of the protein levels of S100A2, p -p65 and FGL2 in U251 (f) and U87 (n); Real-time PCR of S100A2 expression in U251 (g) and U87 (o); Protein levels of FGL2 in cell culture supernatants of U251 (h) and U87 (p) by ELISA assay; PI-FACS = propidium iodide-flow cytometric analysis; ELISA = enzyme-linked immunosorbent assay

    Article Snippet: DNA methylation and gene expression of S100A2; the single CpG methylation levels of S100A2 among (a) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (b) gliomas of grade II to IV and NTBs; (c) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); Gene expression patterns of S100A2 among (d) GBMs (non-G-CIMP and G-CIMP collectively) and NTBs; (e) gliomas of grade II to IV and NTBs; and (f) gliomas with G-CIMP (IDHmut) and non-G-CIMP (IDHwt); (g) Representative S100A2 immunofluorescence staining (left) and the immunoreactivity scores (right) for FFPE samples of gliomas from grade II to IV; (h) Correlation of the single CpG methylation and gene expression of S100A2 in each database; (i) S100A2 single CpG pyrosequencing data in each GBM cell line; (j, k) Real-time PCR and western blots of S100A2 in each GBM cell line; * indicates both the comparison of tumors from TCGA vs. NTB from TCGA and GSE63347 respectively; # indicates each comparison of U251 vs. U373 (or U87 or T98G); NTBs = non-tumor brains; G-CIMP = glioma-CpG island methylator phenotype; IDH mut = IDH mutation; IDH wt = IDH wild type; GBM = glioblastoma; LGG = lower-grade glioma; FFPE = formalin-fixed paraffin-embedded Knockdown of S100A2 by two different shRNA sequences reduces the proliferation rates of U251 and U87 cells ( ).

    Techniques: Expressing, CCK-8 Assay, Double Staining, Migration, Transwell Chamber Assay, Boyden Chamber Assay, Western Blot, Real-time Polymerase Chain Reaction, Cell Culture, Enzyme-linked Immunosorbent Assay